Fund I

  • Industry:

    Pharmaceuticals

  • Transaction Date:

    May 2010

  • Exit Status:

    Exited(October 2010)

  • Website :

Intas Biopharmaceuticals Ltd.

Intas Biopharmaceuticals, set up in year 2000 originally as an independent biotechnology company, is merged with the parent company Intas Pharmaceuticals Ltd. It was India's first biotechnology company to receive European Union- Good Manufacturing Practice (EU-GMP) certification for its manufacturing facility in 2007.


Intas Biologics has an extensive product portfolio of biosimilars across microbial and mammalian cell culture. Its products include Neukine (GCSF), Erykine (EPO), Intalfa (IFN), Pegasta (Peg GCSF), Terifrac (Teriparatide), Mabtas (Rituximab), Folisurge (FSH). In addition to the EU-GMP, the facilities are presently approved by various other regulatory agencies such as ANVISA, GCC, MCC, Indonesia, etc.

Novalead Pharma

We invested in Novalead Pharma, a novel drug discovery platform that addresses life threatening and global unmet medical conditions like diabetic foot ulcers (DFU) and psoriasis. The outcome of our investment is a late-stage DFU asset with global Intellectual Property grants which has reached Phase III status with just under USD 7Mn funds utilized. Novalead is presently at an inflection point with other candidates progressing ahead and readying itself for a monetization strategy.

  • Industry:

    Pharmaceuticals

  • Transaction Date:

    December 2012

  • Exit Status:

    Exited(December 2017)

  • Website :

Amanta Healthcare Limited

In 2012 we invested in sterile manufacturer Amanta which pioneered the launch of branded sterile fluids in India. “Steriport”, with its superior product profile, enabled ease of drug delivery over existing ones with better health outcome for patients. Amanta also exports sterile formulations to over 77 emerging markets thereby improving accessibility of drugs to underpenetrated markets.

  • Industry:

    Single Specialty Healthcare Delivery

  • Transaction Date:

    March 2014

  • Exit Status:

    Exited(September 2016)

  • Website :

Sparsh Nephrocare

In 2014, we invested in Sparsh Nephrocare to bridge the sheer under-penetration of dialysis services in the country. Over the course of 3 years of our investment, Sparsh has added 50+ centers with 300 beds across 12 states improving accessibility of dialysis care in tier II & III locations at an affordable price-point. When we exited the business to global dialysis provider, Fresenius Medical, Sparsh had grown to become the second largest dialysis chain in the country.

Lokmanya Hospitals Pvt. Ltd

We invested in Lokmanya Hospitals, an orthopedic specialty chain based in western Maharashtra for expansion of bed capacity and to bring­­­­ India's first robotic knee replacement technology (NAVIO) to mass market. With this technology the average length of stay of patients has reduced by ~25% while maintaining an affordable delivery model. Since our investment in 2014, the volumes for joint replacement has grown by 10x and Lokmanya Hospitals is now ranked among the top 3 joint replacement centers in the country.

  • Industry:

    Pharmaceutical Packaging

  • Transaction Date:

    October 2015

  • Exit Status:

    Exited(August 2020)

  • Website :

Shriji Polymers (India) Limited

Shriji Polymers, started in 2005, is the largest Indian manufacturer of primary packaging products for export of generic drugs to the regulated markets such as US and Canada. Shriji’s product portfolio includes variety of caps and closures, HDPE bottles, multilayer bottles, Child Resistant Closures and Applicator Devices. The Company has all the marquee pharma companies as customers and is the only Indian company to have a US patent for Child Resistant closures. Shriji has demonstrated global quality at an efficient price point with better turn-around delivery time. The Company has eight manufacturing units, span across India, China and the US.

  • Industry:

    Pharmaceutical

  • Transaction Date:

    November 2015

  • Exit Status:

    Exited(July 2018)

  • Website :

Sai Lifesciences Limited

Our investment in Sai Lifesciences in 2015 has demonstrated India's positioning as a world class base of scientific talent pool combined with state of the art R&D and manufacturing infrastructure. Sai’s offers its customers a distinctive economic advantage by providing a flexible R&D outsourced model while accelerating time to market. At the time of our exit, Sai had established a strong track record of working on 100+ molecules across different phases of the molecular lifecycle which included 3 commercially launched molecules, 12 Phase III molecules and a diversified customer base of 6 out of the top 10 global pharma/biopharma companies.

Brinton Pharmaceuticals

In 2017, we invested in Brinton, a well-positioned play in the fast-growing multi-billion Indian dermatology market. Since then, the company has grown revenues by 3X, catapulted several ranks and has emerged as the fastest growing company in Indian dermatology formulations. Brinton's diversified basket of skincare and haircare products now has a Pan-India reach with repeat prescriptions from 24,000 doctors, 200,000+ pharmacies and 650+ distributors. Brinton is now in the process of repeating the success formula within paediatric segments.

Konverge Healthcare Private Ltd

In March 2017, we backed Konverge to address an identified unmet need of iron and calcium deficit diet in women's nutrition. Konverge now has a reach in over 100 Tier II/Tier III towns extending coverage to low income segments in India. Konverge's differentiated protein strategy through high absorption profile and minimal wastage is presently being nurtured by TCHF through a sharpened strategic direction.